Generation and validation of rapid computational filters for CYP2D6 and CYP3A4

Drug Metabolism and Disposition

Volumn 31, Issue 9, 2003, Pages 1077-1080

  Ekins, Sean ^a   Berbaum, Jennifer ^a   Harrison, Richard K ^a  

^a 19034   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4;

ARTICLE; COMPUTER MODEL; COMPUTER PROGRAM; COST CONTROL; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SYNTHESIS; PRIORITY JOURNAL; STATISTICS; VALIDATION PROCESS;

COMPUTATIONAL BIOLOGY; COUMARINS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUATERNARY AMMONIUM COMPOUNDS; REPRODUCIBILITY OF RESULTS; SOFTWARE;

EID: 0042357537     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.9.1077     Document Type: Article

References (17)

1. Crespi CL, Miller VP. and Penman BW (1997) Microtiter plate assays for inhibition of human drug-metabolizing cytochromes P450. Anal Biochem 248:188-190.
2. Crespi CL, Miller VP, and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res 8:457-471.
3. de Groot MJ and Ekins S (2002) Pharmacophore modeling of cytochromes P450. Adv Drug Deliv Rev 54:367-383.
4. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, and Wrighton SA (1999a) Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 9:477-489.
5. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, and Wrighton SA (1999b) Three-and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J Pharmacol Exp Ther 290:429-438.
6. Ekins S, de Groot M, and Jones JP (2001) Pharmacophore and three dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 29:936-944.
7. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, et al. (2002) Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 61:974-981.
8. Ekins S and Rose JP (2002) In silico ADME/Tox: the state of the art. J Mol Graph Model 20:305-309.
9. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, and Wikel JH (2000) Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods 44:251-272.
10. Gao F, Johnson DL, Ekins S, Janiszewski J, Kelly KG, Meyer RD, and West M (2002) Optimizing higher throughput methods to assess drug-drug interactions for CYPIA2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6 and CYP3A4 in vitro using a single point IC50. J Biomol Screen 7:373-382.
11. Leach AR and Hann MM (2000) The in silico world of virtual libraries. Drug Discov Today 5:326-336.
12. Molnar L and Kesuru GM (2002) A neural network based virtual screening of cytochrome P450 3A4 inhibitors, Bioorg Med Chem Lett 12:419-421.
13. Riley RJ, Parker AJ, Trigg S, and Manners CN (2001) Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm Res (NY) 18:652-655.
14. Smith DA, Ackland MJ, and Jones BC (1997a) Properties of cytochrome P450 isoenzymes and their substrates part 1: active site characteristics. Drug Discov Today 2:406-414.
15. Smith DA, Ackland MJ, and Jones BC (1997b) Properties of cytochrome P450 isoenzymes and their substrates part 2: properties of cytochrome P450 substrates. Drug Discov Today 2:479-486.
16. Wynalda MA and Wienkers LC (1997) Assessment of potential interactions between dopamine agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 25:1211-1214.
17. Young SS, Gombar VK, Emptage MR, Cariello NF, and Lambert C (2002) Mixture deconvolution and analysis of Ames mutagenicity data. Chemo Intell Lab Syst 60:5-11.